{"id":"MELD_3_0.v2","gdl_version":"2.0","concept":"gt0001","language":{"original_language":"ISO_639-1::en"},"description":{"original_author":{"name":"Umiah Gohar, Anna Axell","email":"umiah.gohar@gmail.com","organisation":"Karolinska Institute","date":"2024-03-27"},"lifecycle_state":"Author draft","details":{"en":{"id":"en","keywords":["MELD 3.0 ","transplant","liver","cirrhosis","survival","end stage"],"use":"Values should be no more than 48 hours old.\nMELD can be used on any patient with end stage liver disease irrespective of cirrhosis etiology.\n\nMELD 3.0 improves the accuracy of the MELD calculation by: \n\n• Incorporating additional variables (albumin and sex) \n\n• Updating coefficients for existing variables \n\n• Introducing interaction terms \n\n• Lowering the maximum creatinine value from 4.0 to 3.0 mg/dL.  \n\nMELD 3.0 will apply to all adult liver transplant candidates (registered after turning 18) and to adolescent candidates (age 12-17).  Both male and female adolescent candidates will receive the 1.33 points that will be provided to all adult female candidates. This is based on data that shows there is no sexbased disparity in the adolescent population [3]. ","purpose":"MELD 3.0 is the standard used by the Organ Procurement and Transplantation Network (OPTN) and determines who is the highest priority to receive liver transplants in the US. Predicts estimated 90-day survival. ","misuse":"Only for ages 12 and above.\n\nSeveral conditions are “standard MELD exceptions” and receive a different score:  hepatocellular carcinoma, hepatopulmonary syndrome, portopulmonary hypertension, familial amyloid polyneuropathy, primary hyperoxaluria, cystic fibrosis, hilar cholangiocarcinoma and hepatic artery thrombosis."},"sv":{"id":"sv","purpose":"MELD 3.0 är standarden som används av \"Organ Procurement and Transplantation Network (OPTN)\" och avgör vem som är högst prioriterad att få lever för transplantation i USA. Förutspår beräknad 90-dagars överlevnad.","use":"Värden bör inte vara mer än 48 timmar gamla. \nMELD kan användas på alla patienter med leversjukdom i slutstadiet, oavsett cirros etiologi.\n\nMELD 3.0 förbättrar noggrannheten i MELD-beräkningen genom att: \n\n• Inkludera ytterligare variabler (albumin och kön) \n\n• Uppdatering av koefficienter för befintliga variabler \n\n• Introduktion av interaktionstermer \n\n• Sänkning av det maximala kreatininvärdet från 4,0 till 3,0 mg/dL.  \n\nMELD 3.0 kommer att gälla för alla vuxna levertransplantationskandidater (registrerade efter att ha fyllt 18) och för ungdomskandidater (ålder 12-17).  Både manliga och kvinnliga ungdomskandidater kommer att få de 1,33 poäng som kommer att ges till alla vuxna kvinnliga kandidater. Detta är baserat på data som visar att det inte finns någon könsbaserad skillnad i den unga befolkningen [3].","misuse":"Endast för åldrar 12 och uppåt.\n\nFlera tillstånd är \"standard MELD-undantag\": hepatocellulär cancer (HCC), hepatopulmonellt syndrom, portopulmonell hypertension (PoPH), familjär amyloidos med polyneuropati (FAP), primär hyperoxaluri (PH), cystisk fibros, hilärt kolangiokarcinom och hepatisk artärtrombos.\n","keywords":["MELD 3.0","transplantation","lever","cirros","överlevnad","slutskede"]}},"other_details":{"references":"1. Kim WR, Mannalithara A, Heimbach JK, Kamath PS, Asrani SK, Biggins SW, Wood NL, Gentry SE, Kwong AJ. MELD 3.0: The Model for End-Stage Liver Disease Updated for the Modern Era. Gastroenterology. 2021;161(6):1887-1895.e4. doi:10.1053/j.gastro.2021.08.050. Available from: https://www.sciencedirect.com/science/article/pii/S0016508521034697\n\n\n2. O’Leary JG, Bajaj JS. MELD 3.0: One Small Step for Womankind or One Big Step for Everyone? Gastroenterology. 2022;162(6):1780-1781. doi:10.1053/j.gastro.2021.09.014. Available from: https://www.sciencedirect.com/science/article/pii/S0016508521034934\n\n\n3. Improving Liver Allocation: MELD 3.0 FAQ [Internet]. 2023 Jul 13 [cited 2024 May 21]. Available from: https://optn.transplant.hrsa.gov/media/fyxhlkp5/improving-liver-allocation-meld-30-faq.pdf\n\n\n4. Trivedi, Hirsh D. MD1. The Evolution of the MELD Score and Its Implications in Liver Transplant Allocation: A Beginner's Guide for Trainees. ACG Case Reports Journal 9(5):p e00763, May 2022. | DOI: 10.14309/crj.0000000000000763 \n\n\n5. OPTN MELD serum sodium policy changes [Internet]. 2015 Nov 11 [cited 2024 May 21]. Available from: https://optn.transplant.hrsa.gov/news/meld-serum-sodium-policy-changes/"},"other_contributors":[]},"definition":{"data_bindings":{"gt0002":{"id":"gt0002","type":"INPUT","model_id":"openEHR-EHR-OBSERVATION.basic_demographic_egf.v1","template_id":"openEHR-EHR-OBSERVATION.basic_demographic_egf.v1","elements":{"gt0003":{"id":"gt0003","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0004]"},"gt0067":{"id":"gt0067","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0013]"}}},"gt0004":{"id":"gt0004","type":"INPUT","model_id":"openEHR-EHR-OBSERVATION.lab_test-liver_function.v1","template_id":"openEHR-EHR-OBSERVATION.lab_test-liver_function.v1","elements":{"gt0005":{"id":"gt0005","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0078.4]"}}},"gt0008":{"id":"gt0008","type":"INPUT","model_id":"openEHR-EHR-OBSERVATION.laboratory_test_result-serum_albumin.v0","template_id":"openEHR-EHR-OBSERVATION.laboratory_test_result-serum_albumin.v0","elements":{"gt0009":{"id":"gt0009","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0.121]"}}},"gt0010":{"id":"gt0010","type":"INPUT","model_id":"openEHR-EHR-OBSERVATION.inr.v0","template_id":"openEHR-EHR-OBSERVATION.inr.v0","elements":{"gt0011":{"id":"gt0011","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0004]"}}},"gt0012":{"id":"gt0012","type":"INPUT","model_id":"openEHR-EHR-OBSERVATION.lab_test-fractional_sodium_excretion.v1","template_id":"openEHR-EHR-OBSERVATION.lab_test-fractional_sodium_excretion.v1","elements":{"gt0013":{"id":"gt0013","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0078.5.1]"}}},"gt0014":{"id":"gt0014","type":"OUTPUT","model_id":"openEHR-EHR-OBSERVATION.basic_demographic_egf.v1","template_id":"openEHR-EHR-OBSERVATION.basic_demographic_egf.v1","elements":{"gt0015":{"id":"gt0015","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0004]"},"gt0068":{"id":"gt0068","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0013]"}}},"gt0016":{"id":"gt0016","type":"OUTPUT","model_id":"openEHR-EHR-OBSERVATION.lab_test-liver_function.v1","template_id":"openEHR-EHR-OBSERVATION.lab_test-liver_function.v1","elements":{"gt0017":{"id":"gt0017","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0078.4]"}}},"gt0018":{"id":"gt0018","type":"INPUT","model_id":"openEHR-EHR-OBSERVATION.lab_test_creatinine.v1","template_id":"openEHR-EHR-OBSERVATION.lab_test_creatinine.v1","elements":{"gt0019":{"id":"gt0019","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0005]"}}},"gt0020":{"id":"gt0020","type":"OUTPUT","model_id":"openEHR-EHR-OBSERVATION.lab_test_creatinine.v1","template_id":"openEHR-EHR-OBSERVATION.lab_test_creatinine.v1","elements":{"gt0021":{"id":"gt0021","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0005]"}}},"gt0022":{"id":"gt0022","type":"OUTPUT","model_id":"openEHR-EHR-OBSERVATION.laboratory_test_result-serum_albumin.v0","template_id":"openEHR-EHR-OBSERVATION.laboratory_test_result-serum_albumin.v0","elements":{"gt0023":{"id":"gt0023","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0.121]"}}},"gt0024":{"id":"gt0024","type":"OUTPUT","model_id":"openEHR-EHR-OBSERVATION.inr.v0","template_id":"openEHR-EHR-OBSERVATION.inr.v0","elements":{"gt0025":{"id":"gt0025","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0004]"}}},"gt0026":{"id":"gt0026","type":"OUTPUT","model_id":"openEHR-EHR-OBSERVATION.lab_test-fractional_sodium_excretion.v1","template_id":"openEHR-EHR-OBSERVATION.lab_test-fractional_sodium_excretion.v1","elements":{"gt0027":{"id":"gt0027","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0078.5.1]"}}},"gt0054":{"id":"gt0054","type":"OUTPUT","model_id":"openEHR-EHR-OBSERVATION.meld_score.v1","template_id":"openEHR-EHR-OBSERVATION.meld_score.v1","elements":{"gt0055":{"id":"gt0055","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0005]"}}},"gt0058":{"id":"gt0058","type":"OUTPUT","model_id":"openEHR-EHR-EVALUATION.meld_score.v1","template_id":"openEHR-EHR-EVALUATION.meld_score.v1","elements":{"gt0059":{"id":"gt0059","path":"/data[at0001]/items[at0002]"}}}},"rules":{"gt0049":{"id":"gt0049","priority":21,"then":["$gt0050|Boolean_gender| = 1"],"when":["$gt0003|Gender| == local::at0006|Female|"],"description":""},"gt0051":{"id":"gt0051","priority":20,"then":["$gt0050|Boolean_gender| = 0"],"when":["$gt0003|Gender| == local::at0005|Male|"],"description":""},"gt0069":{"id":"gt0069","priority":19,"then":["$gt0050|Boolean_gender| = 1"],"when":["$gt0067|Age| < 18,a && $gt0067|Age| >= 12,a"]},"gt0044":{"id":"gt0044","priority":18,"then":["$gt0045|Albumin conversion factor| = 10.0"],"when":["$gt0009|Serum Albumin|.unit == 'gm/l'"],"description":""},"gt0070":{"id":"gt0070","priority":17,"then":["$gt0023|Serum Albumin|.magnitude = $gt0009|Serum Albumin|.magnitude * $gt0045|Albumin conversion factor|","$gt0023|Serum Albumin|.precision = 2","$gt0023|Serum Albumin|.unit = 'gm/dl'"],"when":["$gt0009|Serum Albumin| != null"]},"gt0048":{"id":"gt0048","priority":16,"then":["$gt0023|Serum Albumin| = 3.5,gm/dl"],"when":["$gt0023|Serum Albumin| > 3.5,gm/dl"],"description":""},"gt0047":{"id":"gt0047","priority":15,"then":["$gt0023|Serum Albumin| = 1.5,gm/dl"],"when":["$gt0023|Serum Albumin| < 1.5,gm/dl"],"description":""},"gt0042":{"id":"gt0042","priority":14,"then":["$gt0025|INR| = 1,1"],"when":["$gt0011|INR| < 1,1"],"description":""},"gt0071":{"id":"gt0071","priority":13,"then":["$gt0025|INR| = $gt0011|INR|"],"when":["$gt0011|INR| >= 1,1"],"description":""},"gt0039":{"id":"gt0039","priority":12,"then":["$gt0027|serum Sodium (sNa)| = $gt0013|serum Sodium (sNa)|","$gt0027|serum Sodium (sNa)|.unit = 'mmol/l'"],"when":["( $gt0013|serum Sodium (sNa)|.magnitude >= 125 ) && ( $gt0013|serum Sodium (sNa)|.magnitude <= 137 )"]},"gt0072":{"id":"gt0072","priority":11,"then":["$gt0027|serum Sodium (sNa)|.magnitude = 125","$gt0027|serum Sodium (sNa)|.unit = 'mmol/l'"],"when":["$gt0013|serum Sodium (sNa)| < 125,mmol/l"]},"gt0041":{"id":"gt0041","priority":10,"then":["$gt0027|serum Sodium (sNa)|.magnitude = 137","$gt0027|serum Sodium (sNa)|.unit = 'mmol/l'"],"when":["( $gt0013|serum Sodium (sNa)|.magnitude > 137,mmol/l )"],"description":""},"gt0032":{"id":"gt0032","priority":9,"then":["$gt0033|Creatinine conversion factor| = 88.4"],"when":["$gt0019|Serum Creatinine|.unit == 'µmol/l'"]},"gt0034":{"id":"gt0034","priority":8,"then":["$gt0021|Serum Creatinine|.magnitude = $gt0019|Serum Creatinine|.magnitude / $gt0033|Creatinine conversion factor|","$gt0021|Serum Creatinine|.precision = 2","$gt0021|Serum Creatinine|.unit = 'mg/dl'"],"when":["$gt0019|Serum Creatinine| != null"]},"gt0036":{"id":"gt0036","priority":7,"then":["$gt0021|Serum Creatinine| = 3,mg/dl"],"when":["$gt0021|Serum Creatinine| > 3,mg/dl"],"description":""},"gt0035":{"id":"gt0035","priority":6,"then":["$gt0021|Serum Creatinine| = 1,mg/dl"],"when":["$gt0021|Serum Creatinine| < 1,mg/dl"],"description":""},"gt0028":{"id":"gt0028","priority":5,"then":["$gt0029|Bilirubin conversion factor| = 17.1"],"when":["$gt0005|Total bilirubin|.unit == 'µmol/l'"],"description":""},"gt0030":{"id":"gt0030","priority":4,"then":["$gt0017|Total bilirubin|.magnitude = $gt0005|Total bilirubin|.magnitude / $gt0029|Bilirubin conversion factor|","$gt0017|Total bilirubin|.precision = 2","$gt0017|Total bilirubin|.unit = 'mg/dl'"],"when":["$gt0005|Total bilirubin| != null"]},"gt0031":{"id":"gt0031","priority":3,"then":["$gt0017|Total bilirubin| = 1,mg/dl","$gt0017|Total bilirubin|.precision = 2"],"when":["$gt0017|Total bilirubin| < 1,mg/dl"],"description":""},"gt0052":{"id":"gt0052","priority":2,"then":["$gt0055|MELD score 3.0|.magnitude = 1.33 * ( $gt0050|Boolean_gender| ) + ( 4.56 * log ( $gt0017|Total bilirubin|.magnitude ) ) + ( 0.82 * ( 137 - $gt0027|serum Sodium (sNa)|.magnitude ) ) - ( 0.24 * ( 137 - $gt0027|serum Sodium (sNa)|.magnitude ) * log ( $gt0017|Total bilirubin|.magnitude ) ) + ( 9.09 * log ( $gt0025|INR|.magnitude ) ) + ( 11.14 * log ( $gt0021|Serum Creatinine|.magnitude ) ) + ( 1.85 * ( 3.5 - $gt0023|Serum Albumin|.magnitude ) ) - ( 1.83 * ( 3.5 - $gt0023|Serum Albumin|.magnitude ) * log ( $gt0021|Serum Creatinine|.magnitude ) ) + 6"],"when":["$gt0017|Total bilirubin| != null","$gt0023|Serum Albumin| != null","$gt0011|INR| != null","$gt0027|serum Sodium (sNa)| != null","$gt0021|Serum Creatinine| != null"],"description":"Predicts three-month survival in patients (age 12+) with liver cirrhosis,  with higher scores correlating with increased severity of liver dysfunction."},"gt0066":{"id":"gt0066","priority":1,"then":["$gt0059|Estimated 90-day survival| = ( 0.946 ^ exp ( 0.17698 * $gt0055|MELD score 3.0|.magnitude - 3.56 ) ) * 100"],"when":["$gt0055|MELD score 3.0|.magnitude != null"],"description":"Estimated 90-day survival = 0.946exp(0.17698*MELD 3.0 – 3.56) * 100"}},"default_actions":["$gt0045|Albumin conversion factor| = 1","$gt0033|Creatinine conversion factor| = 1","$gt0029|Bilirubin conversion factor| = 1","$gt0038|Sodium conversion factor| = 1","$gt0050|Boolean_gender| = 1"],"pre_conditions":["$gt0067|Age|.magnitude >= 12"]},"ontology":{"term_definitions":{"en":{"id":"en","terms":{"gt0001":{"text":"MELD 3.0","description":"MELD 3.0, implemented 2023, is the current standard calculation for organ transplantation consideration in the United States.\n\nMELD 3.0 will address the sex-based disparity that has existed in liver allocation since the original MELD score was implemented. MELD 3.0 includes 1.33 points for candidates who are female. In addition, MELD 3.0 better predicts risk of waitlist mortality for all liver candidates compared to the earlier versions of MELD, by updating the coefficients for each of the variables in the score, adding albumin as a factor, introducing interaction terms, and lowering the maximum creatinine value from 4.0 to 3.0 mg/dL.  Thus providing patients a meaningfully higher chance of receiving an organ and possibly averting death compared to MELD NA score [1]. Furthermore, MELD 3.0 also finally addresses the disadvantage that women have faced in the liver allocation system since the inception of MELD [2].\n\nMELD 3.0 improves the accuracy of the MELD calculation by: \n\n• Incorporating additional variables (albumin and sex)\n\n• Updating coefficients for existing variables • Introducing interaction terms \n\n• Lowering the maximum creatinine value from 4.0 to 3.0 mg/dL [3]. \n\nFORMULA:\n\nMELD 3.0 = 1.33*(Female) + 4.56*ln(Serum bilirubin) + 0.82*(137 - Sodium) – 0.24*(137 - Sodium)*ln(Serum bilirubin) + 9.09*ln(INR) + 11.14*ln(Serum creatinine) + 1.85*(3.5 – Serum albumin) – 1.83*(3.5 – Serum albumin)*ln(Serum creatinine) + 6, rounded to the nearest integer\n\nAdditional rules:\n\nSerum bilirubin, INR, and serum creatinine values below 1.0 are set to 1.0.\nSodium is limited to a range of 125-137 mEq/L, and if outside of these bounds, is set to the nearest limit.\nSerum albumin is limited to a range of 1.5-3.5 g/dL, and if outside of these bounds, is set to the nearest limit.\nMaximum serum creatinine is 3.0 mg/dL, and if above this bound, is set to 3.0 mg/dL.\n\nEstimated 90-day survival = 0.946exp(0.17698*MELD 3.0 – 3.56) * 100","id":"gt0001"},"gt0003":{"text":"Gender","description":"i","id":"gt0003"},"gt0005":{"text":"Total bilirubin","description":"i","id":"gt0005"},"gt0009":{"text":"Serum Albumin","description":"i","id":"gt0009"},"gt0011":{"text":"INR","description":"i","id":"gt0011"},"gt0013":{"text":"serum Sodium (sNa)","description":"i","id":"gt0013"},"gt0015":{"text":"Gender","id":"gt0015"},"gt0017":{"id":"gt0017","text":"Total bilirubin"},"gt0019":{"text":"Serum Creatinine","description":"i","id":"gt0019"},"gt0021":{"id":"gt0021","text":"Serum Creatinine"},"gt0023":{"id":"gt0023","text":"Serum Albumin"},"gt0025":{"id":"gt0025","text":"INR"},"gt0027":{"id":"gt0027","text":"serum Sodium (sNa)"},"gt0028":{"id":"gt0028","text":"Bilirubin conversion rule","description":""},"gt0029":{"text":"Bilirubin conversion factor","id":"gt0029"},"gt0030":{"id":"gt0030","text":"Bilirubin µmol/L to mg/dL","description":""},"gt0031":{"id":"gt0031","text":"Bilirubin <1  mg/dL","description":""},"gt0032":{"id":"gt0032","text":"Creatinine conversion rule","description":""},"gt0033":{"text":"Creatinine conversion factor","id":"gt0033"},"gt0034":{"id":"gt0034","text":"Creatinine µmol to mg/dL","description":""},"gt0035":{"id":"gt0035","text":"Creatinine <1 mg/dL","description":""},"gt0036":{"id":"gt0036","text":"Creatinine >3 mg/dL","description":""},"gt0038":{"text":"Sodium conversion factor","id":"gt0038"},"gt0039":{"id":"gt0039","text":"Sodium normal range","description":"No need for conversion mmol/L -> mEq/L, conversion factor = 1."},"gt0041":{"id":"gt0041","text":"Sodium >137","description":""},"gt0042":{"id":"gt0042","text":"INR <1","description":""},"gt0044":{"id":"gt0044","text":"Albumin conversion rule","description":""},"gt0045":{"text":"Albumin conversion factor","id":"gt0045"},"gt0047":{"id":"gt0047","text":"Albumin <1.5","description":""},"gt0048":{"id":"gt0048","text":"Albumin >3.5","description":""},"gt0049":{"id":"gt0049","text":"Gender Female","description":""},"gt0050":{"text":"Boolean_gender","id":"gt0050"},"gt0051":{"id":"gt0051","text":"Gender Male","description":""},"gt0052":{"text":"MELD 3.0 score","id":"gt0052"},"gt0055":{"text":"MELD score 3.0","description":"Predicts three-month survival in patients (age 12+) waiting for liver transplant.","id":"gt0055"},"gt0059":{"id":"gt0059","text":"Estimated 90-day survival"},"gt0066":{"id":"gt0066","text":"90-day survival score","description":"Estimated 90-day survival = 0.946exp(0.17698*MELD 3.0 – 3.56) * 100"},"gt0067":{"text":"Age","description":"i","id":"gt0067"},"gt0068":{"id":"gt0068","text":"Age"},"gt0069":{"text":"Adolescent = Female","description":"Both male and female adolescent candidates will receive the 1.33 points that will be provided to all adult female candidates. This is based on data that shows there is no sexbased disparity in the adolescent population.","id":"gt0069"},"gt0070":{"id":"gt0070","text":"Albumin g/L to g/dL","description":""},"gt0071":{"id":"gt0071","text":"INR >1","description":""},"gt0072":{"id":"gt0072","text":"Sodium <125","description":""}}},"sv":{"id":"sv","terms":{"gt0001":{"text":"MELD 3.0","description":"MELD 3.0, implementerad 2023, är den nuvarande standardberäkningen för organtransplantation i USA.\n\nMELD 3.0 tar itu med den könsbaserade skillnaden som har funnits gällande allokering av lever för transplantation sedan den ursprungliga MELD-poängen implementerades. MELD 3.0 inkluderar 1,33 poäng för kvinnliga kandidater. Dessutom förutsäger MELD 3.0 bättre risken för dödlighet på väntelistan för alla leverkandidater jämfört med de tidigare versionerna av MELD, genom att uppdatera koefficienterna för var och en av variablerna i poängen, lägga till albumin som en faktor, introducera interaktionstermer och sänka den maximala kreatininvärde från 4,0 till 3,0 mg/dL.  Detta ger patienterna en meningsfullt högre chans att få ett organ och möjligen avvärja döden jämfört med MELD NA [1]. Dessutom tar MELD 3.0 även upp de nackdelar som kvinnor har mött i leverallokeringssystemet sedan starten av MELD [2].\n\nMELD 3.0 förbättrar noggrannheten i MELD-beräkningen genom att: \n\n• Inkludera ytterligare variabler (albumin och kön)\n\n• Uppdatering av koefficienter för befintliga variabler • Införande av interaktionstermer \n\n• Sänkning av det maximala kreatininvärdet från 4,0 till 3,0 mg/dL [3]. \n\nFORMEL:\n\nMELD 3,0 = 1,33*(Kvinna) + 4,56*ln(serumbilirubin) + 0,82*(137 - Natrium) – 0,24*(137 - Natrium)*ln(serumbilirubin) + 9,09*ln(INR)* + 11(11. Serumkreatinin) + 1,85*(3,5 – Serumalbumin) – 1,83*(3,5 – Serumalbumin)*ln(Serumkreatinin) + 6, avrundat till närmaste heltal\n\nYtterligare regler:\n\nSerumbilirubin, INR och serumkreatininvärden under 1,0 är inställda på 1,0.\nNatrium är begränsat till ett intervall på 125-137 mEq/L, och om det ligger utanför dessa gränser, sätts det till närmaste gräns.\nSerumalbumin är begränsat till intervallet 1,5-3,5 g/dL, och om det ligger utanför dessa gränser, sätts det till närmaste gräns.\nMaximalt serumkreatinin är 3,0 mg/dL, och om det överstiger denna gräns är det satt till 3,0 mg/dL.\n\nBeräknad 90-dagars överlevnad = 0,946exp(0,17698*MELD 3,0 – 3,56) * 100","id":"gt0001"},"gt0003":{"text":"Kön","description":"i","id":"gt0003"},"gt0005":{"text":"Totalt bilirubin","description":"i","id":"gt0005"},"gt0009":{"text":"Serumalbumin","description":"i","id":"gt0009"},"gt0011":{"text":"PK (INR)","description":"i","id":"gt0011"},"gt0013":{"text":"Serumnatrium","description":"i","id":"gt0013"},"gt0015":{"text":"Kön","id":"gt0015"},"gt0017":{"text":"Totalt bilirubin","id":"gt0017"},"gt0019":{"text":"Serumkreatinin","description":"i","id":"gt0019"},"gt0021":{"text":"Serumkreatinin","id":"gt0021"},"gt0023":{"text":"Serumalbumin","id":"gt0023"},"gt0025":{"text":"PK (INR)","id":"gt0025"},"gt0027":{"text":"Serumnatrium","id":"gt0027"},"gt0028":{"text":"Bilirubin omvandlingsregel","id":"gt0028"},"gt0029":{"text":"Bilirubin omvandlingsfaktor","id":"gt0029"},"gt0030":{"text":"Bilirubin µmol/L till mg/dL","id":"gt0030"},"gt0031":{"text":"Bilirubin <1  mg/dL","id":"gt0031"},"gt0032":{"text":"Kreatinin omvandlingsregel","id":"gt0032"},"gt0033":{"text":"Kreatinin omvandlingsfaktor","id":"gt0033"},"gt0034":{"text":"Kreatinin µmol till mg/dL","id":"gt0034"},"gt0035":{"text":"Kreatinin <1 mg/dL","id":"gt0035"},"gt0036":{"text":"Kreatinin >3 mg/dL","id":"gt0036"},"gt0038":{"text":"Natrium omvandlingsfaktor","id":"gt0038"},"gt0039":{"text":"Natrium normalintervall","description":"Inget behov av konvertering mmol/L till mEq/L, omvandlingsfaktor = 1","id":"gt0039"},"gt0041":{"text":"Natrium >137","id":"gt0041"},"gt0042":{"text":"PK (INR) <1","id":"gt0042"},"gt0044":{"text":"Albumin omvandlingsregel","id":"gt0044"},"gt0045":{"text":"Albumin omvandlingsfaktor","id":"gt0045"},"gt0047":{"text":"Albumin <1.5","id":"gt0047"},"gt0048":{"text":"Albumin >3.5","id":"gt0048"},"gt0049":{"text":"Kvinnligt kön","id":"gt0049"},"gt0050":{"text":"Booleskt_kön","id":"gt0050"},"gt0051":{"text":"Manligt kön","id":"gt0051"},"gt0052":{"text":"MELD 3.0 poängställning","id":"gt0052"},"gt0055":{"text":"MELD 3.0 poängställning","description":"Beräknar tremånaders överlevnad hos patienter (ålder 12+) som väntar på levertransplantation.","id":"gt0055"},"gt0059":{"text":"Beräknad 90-dagars överlevnad","id":"gt0059"},"gt0066":{"text":"90-dagars överlevnadspoängställning","description":"Beräknad 90-dagars överlevnad = 0.946exp(0.17698*MELD 3.0 – 3.56) * 100","id":"gt0066"},"gt0067":{"text":"Ålder","description":"i","id":"gt0067"},"gt0068":{"text":"Ålder","id":"gt0068"},"gt0069":{"text":"Tonåring = Kvinnligt kön","description":"Både manliga och kvinnliga tonårspatienter kommer att få de 1,33 poäng som kommer att ges till alla vuxna kvinnliga kandidater. Detta är baserat på data som visar att det inte finns någon könsbaserad skillnad i den unga befolkningen. ","id":"gt0069"},"gt0070":{"text":"Albumin g/L till g/dL","id":"gt0070"},"gt0071":{"text":"PK (INR) >1","id":"gt0071"},"gt0072":{"text":"Natrium <125","id":"gt0072"}}}},"term_bindings":{"LOINC":{"id":"LOINC","bindings":{"gt0011":{"termId":"gt0011","termText":"INR","codes":["LOINC::6301-6"],"terminology":"LOINC"},"gt0025":{"termId":"gt0025","termText":"INR","codes":["LOINC::6301-6"],"terminology":"LOINC"},"gt0005":{"termId":"gt0005","termText":"Total bilirubin","codes":["LOINC::42719-5"],"terminology":"LOINC"},"gt0017":{"termId":"gt0017","termText":"Total bilirubin","codes":["LOINC::42719-5"],"terminology":"LOINC"},"gt0023":{"termId":"gt0023","termText":"Serum Albumin","codes":["LOINC::1751-7"],"terminology":"LOINC"},"gt0013":{"termId":"gt0013","termText":"serum Sodium (sNa)","codes":["LOINC::2947-0"],"terminology":"LOINC"},"gt0027":{"termId":"gt0027","termText":"serum Sodium (sNa)","codes":["LOINC::2947-0"],"terminology":"LOINC"},"gt0009":{"termId":"gt0009","termText":"Serum Albumin","codes":["LOINC::\t1751-7"],"terminology":"LOINC"},"gt0019":{"termId":"gt0019","termText":"Serum Creatinine","codes":["LOINC::38483-4"],"terminology":"LOINC"},"gt0021":{"termId":"gt0021","termText":"Serum Creatinine","codes":["LOINC::38483-4"],"terminology":"LOINC"}}}}}}